Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Figure 1: Changes in fall latency during the rotarod test across the three different experimental groups
While Primes clinical teams share a deep dive of whats next in the GLP-1 pipeline in the quarterly GLP-1 Pipeline Update, lets explore some of the top GLP-1 drug pipeline trends
Obesity is no longer regarded as simply a failure of willpower but now a chronic illness with a biological cause (Couzin-Frankel Dec 2023)
Who Can Benefit: Navigating the Potential of Retatrutide As the potential of Retatrutide unfolds raises the question of who stands to benefit from this groundbreaking medication
Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, represents the frontier of this drug class
